Improved Staging of Patients With Carcinoid and Islet Cell Tumors With <sup>18</sup>F-Dihydroxy-Phenyl-Alanine and <sup>11</sup>C-5-Hydroxy-Tryptophan Positron Emission Tomography

Koopmans, Klaas Pieter; Neels, Oliver; Kema, Ido P.; Elsinga, Philip H.; Sluiter, Wim J.; Vanghillewe, Koen; Brouwers, Adrienne H.; Jager, Pieter L.; Vries, Elisabeth G.E. de

doi:10.1200/jco.2007.15.1126

Cited by 222 publications

(160 citation statements)

References 20 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…DOPA PET appears to show promise in the evaluation of pancreatic NETs. Koopmans et al [94] in the evaluation of 23 patients with pancreatic islet cell tumors reported a sensitivity of 89% using 18F-DOPA PET, as compared with 78% and 87% for gamma-based SRS and conventional CT, respectively.…”

Section: Tan Eh Et Al Imaging Of Gastroenteropancreatic Netsmentioning

confidence: 99%

Imaging of gastroenteropancreatic neuroendocrine tumors

Tan

Tan²

2011

WJCO

View full text Add to dashboard Cite

Imaging of gastroenteropancreatic neuroendocrine tumors can be broadly divided into anatomic and functional techniques. Anatomic imaging determines the local extent of the primary lesion, providing crucial information required for surgical planning. Functional imaging, not only determines the extent of metastatic disease spread, but also provides important information with regard to the biologic behavior of the tumor, allowing clinicians to decide on the most appropriate forms of treatment. We review the current literature on this subject, with emphasis on the strengths of each imaging modality.

show abstract

Section: Tan Eh Et Al Imaging Of Gastroenteropancreatic Netsmentioning

confidence: 99%

Imaging of gastroenteropancreatic neuroendocrine tumors

Tan

Tan²

2011

WJCO

View full text Add to dashboard Cite

show abstract

“…11 C-5-HT and 18 F-DOPA may have a role in patients with pancreatic and intestinal NENs that have negative or inconclusive results on SSTR-based imaging (Koopmans et al 2008).…”

Section: R166mentioning

confidence: 99%

Neuroendocrine tumor disease: an evolving landscape

Frilling

Åkerström

Falconi

et al. 2012

Endocrine-Related Cancer

147

106

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent a heterogenous group of tumors arising from a variety of neuroendocrine cell types. The incidence and prevalence of GEPNENs have markedly increased over the last three decades. Symptoms are often absent in early disease, or vague and nonspecific even in advanced disease. Delayed diagnosis is thus common. Chromogranin A is the most commonly used biomarker but has limitations as does the proliferative marker Ki-67%, which is often used for tumor grading and determination of therapy. The development of a multidimensional prognostic nomogram may be valuable in predicting tumor behavior and guiding therapy but requires validation. Identification of NENs that express somatostatin receptors (SSTR) allows for SSTR scintigraphy and positron emission tomography imaging using novel radiolabeled compounds. Complete surgical resection of limited disease or endoscopic ablation of small lesions localized in stomach or rectum can provide cure; however, the majority of GEP-NENs are metastatic (most frequently the liver and/or mesenteric lymph nodes) at diagnosis. Selected patients with metastatic disease may benefit from advanced surgical techniques including hepatic resection or liver transplantation. Somatostatin analogs are effective for symptomatic treatment and exhibit some degree of antiproliferative activity in small intestinal NENs. There is a place for streptozotocin, temozolomide, and capecitabine in the management of pancreatic NENs, while new agents targeting either mTOR (everolimus) or angiogenic (sunitinib) pathways have shown efficacy in these lesions.

show abstract

“…In the case of negative SRS results, a PET/CT examination should be considered after the administration of 18 FDOPA, and for G2 and G3 NENs, PET/CT scan after the administration of 18 FDG [22,23].…”

Section: Other Imaging Examinationsmentioning

confidence: 99%

Nowotwory neuroendokrynne jelita grubego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Starzyńska

Deptała

Królicki

et al. 2014

Endokrynologia Polska

View full text Add to dashboard Cite

Neuroendocrine neoplasms of the large intestine account for 20% of all neuroendocrine neoplasms (NENs) and are most commonly found in the rectum. The rate of detection of colorectal NENs is increasing, and this tendency will continue due to the widespread use of colonoscopy as a screening tool and the removal of all diagnosed lesions. This paper provides updated guidelines for the management of patients with colorectal NENs. Recent data on epidemiology, clinical characteristics, biochemical, and pathomorphological diagnosis as well as useful imaging techniques are presented. We look in detail at novel methods of treatment including endoscopic and surgical management, pharmacological and radioisotope therapy. We summarise monitoring of the treatment. (Endokrynol Pol 2013; 64 (6): 494-504)

show abstract

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With ¹⁸F-Dihydroxy-Phenyl-Alanine and ¹¹C-5-Hydroxy-Tryptophan Positron Emission Tomography

Abstract: (18)F-DOPA PET/CT is the optimal imaging modality for staging in carcinoid patients and (11)C-5-HTP PET/CT in islet cell tumor patients.

Cited by 222 publications

References 20 publications

Imaging of gastroenteropancreatic neuroendocrine tumors

Imaging of gastroenteropancreatic neuroendocrine tumors

Neuroendocrine tumor disease: an evolving landscape

Nowotwory neuroendokrynne jelita grubego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Contact Info

Product

Resources

About

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission Tomography

Abstract: (18)F-DOPA PET/CT is the optimal imaging modality for staging in carcinoid patients and (11)C-5-HTP PET/CT in islet cell tumor patients.

Cited by 222 publications

References 20 publications

Imaging of gastroenteropancreatic neuroendocrine tumors

Imaging of gastroenteropancreatic neuroendocrine tumors

Neuroendocrine tumor disease: an evolving landscape

Nowotwory neuroendokrynne jelita grubego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Contact Info

Product

Resources

About

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With ¹⁸F-Dihydroxy-Phenyl-Alanine and ¹¹C-5-Hydroxy-Tryptophan Positron Emission Tomography